The award will go to David Alland to create an Ebola test using the same technology as a TB assay marketed by Cepheid.
The portable analyzer runs an RT-qPCR-based Ebola assay and takes about 75 minutes to detect the presence of the virus from whole blood.
BioInnovation Solutions, formerly Pathogenica, and Enzymatics are developing a rapid Ebola diagnostic and have validated it on patient samples in Nigeria.
The tests use the company's Nanotrap reagents, hydrogel nanoparticles functionalized with internal affinity baits to enrich target analytes for downstream analysis.
Qiagen announced today it will offer global distribution of the Altona Diagnostics RealStar Ebolavirus RT-PCR Kit 1.0.
The firms intend to seek Emergency Use Authorization from the US Food and Drug Administration once the Ebola assay is developed.
Point-of-care testing, automation, and panelization of nucleic acid amplification testing are the future of the clinical lab ― and will likely change how labs and clinicians relate.
The method may be deployed as part of the Broad's collaboration with Illumina and USAID to study Ebola in some West African countries hit by the outbreak.
The Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation awarded the grant to Cepheid to develop the test.
Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.
A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.
At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.
In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.